PURPOSE: FIAU, (1-(2'-deoxy-2'-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil) has been used as a substrate for herpes simplex virus thymidine kinases (HSV-TK and HSV-tk, for protein and gene expression, respectively) and other bacterial and viral thymidine kinases for noninvasive imaging applications. Previous studies have reported the formation of a de-iodinated metabolite of 18F-FIAU. This study reports the dynamic tumor uptake, biodistribution, and metabolite contribution to the activity of 18F-FIAU seen in HSV-tk gene expressing tumors and compares the distribution properties with its de-iodinated metabolite 18F-FAU. METHODS: CD-1 nu/nu mice with subcutaneous MH3924A and MH3924A-stb-tk+ xenografts on opposite flanks were used for the biodistribution and imaging studies. Mice were injected IV with either 18F-FIAU or 18F-FAU. Mice underwent dynamic imaging with each tracer for 65 min followed by additional static imaging up to 150 min post-injection for some animals. Animals were sacrificed at 60 or 150 min post-injection. Samples of blood and tissue were collected for biodistribution and metabolite analysis. Regions of interest were drawn over the images obtained from both tumors to calculate the time-activity curves. RESULTS: Biodistribution and imaging studies showed the highest uptake of 18F-FIAU in the MH3924A-stb-tk+ tumors. Dynamic imaging studies revealed a continuous accumulation of 18F-FIAU in HSV-TK expressing tumors over 60 min. The mean biodistribution values (SUV ± SE) for MH3924A-stb-tk+ were 2.07 ± 0.40 and 6.15 ± 1.58 and that of MH3924A tumors were 0.19 ± 0.07 and 0.47 ± 0.06 at 60 and 150 min, respectively. In 18F-FIAU injected mice, at 60 min nearly 63% of blood activity was present as its metabolite 18F-FAU. Imaging and biodistribution studies with 18F-FAU demonstrated no specific accumulation in MH3924A-stb-tk+ tumors and SUVs for both the tumors were similar to those observed with muscle. CONCLUSION: 18F-FIAU shows a continuous accumulation of activity in HSV-TK expressing tumors. 18F-FAU does not show any preferential accumulation in HSV-TK expressing tumors. In the 18F-FIAU treated mice, the 18F-FAU contribution to the total uptake seen in HSV-TK positive tumors is minimal.
PURPOSE:FIAU, (1-(2'-deoxy-2'-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil) has been used as a substrate for herpes simplex virus thymidine kinases (HSV-TK and HSV-tk, for protein and gene expression, respectively) and other bacterial and viral thymidine kinases for noninvasive imaging applications. Previous studies have reported the formation of a de-iodinated metabolite of 18F-FIAU. This study reports the dynamic tumor uptake, biodistribution, and metabolite contribution to the activity of 18F-FIAU seen in HSV-tk gene expressing tumors and compares the distribution properties with its de-iodinated metabolite 18F-FAU. METHODS:CD-1 nu/nu mice with subcutaneous MH3924A and MH3924A-stb-tk+ xenografts on opposite flanks were used for the biodistribution and imaging studies. Mice were injected IV with either 18F-FIAU or 18F-FAU. Mice underwent dynamic imaging with each tracer for 65 min followed by additional static imaging up to 150 min post-injection for some animals. Animals were sacrificed at 60 or 150 min post-injection. Samples of blood and tissue were collected for biodistribution and metabolite analysis. Regions of interest were drawn over the images obtained from both tumors to calculate the time-activity curves. RESULTS: Biodistribution and imaging studies showed the highest uptake of 18F-FIAU in the MH3924A-stb-tk+ tumors. Dynamic imaging studies revealed a continuous accumulation of 18F-FIAU in HSV-TK expressing tumors over 60 min. The mean biodistribution values (SUV ± SE) for MH3924A-stb-tk+ were 2.07 ± 0.40 and 6.15 ± 1.58 and that of MH3924Atumors were 0.19 ± 0.07 and 0.47 ± 0.06 at 60 and 150 min, respectively. In 18F-FIAU injected mice, at 60 min nearly 63% of blood activity was present as its metabolite 18F-FAU. Imaging and biodistribution studies with 18F-FAU demonstrated no specific accumulation in MH3924A-stb-tk+ tumors and SUVs for both the tumors were similar to those observed with muscle. CONCLUSION:18F-FIAU shows a continuous accumulation of activity in HSV-TK expressing tumors. 18F-FAU does not show any preferential accumulation in HSV-TK expressing tumors. In the 18F-FIAU treated mice, the 18F-FAU contribution to the total uptake seen in HSV-TK positive tumors is minimal.
Authors: Chetan Bettegowda; Catherine A Foss; Ian Cheong; Yuchuan Wang; Luis Diaz; Nishant Agrawal; James Fox; James Dick; Long H Dang; Shibin Zhou; Kenneth W Kinzler; Bert Vogelstein; Martin G Pomper Journal: Proc Natl Acad Sci U S A Date: 2005-01-14 Impact factor: 11.205
Authors: U Haberkorn; A Altmann; I Morr; K W Knopf; C Germann; R Haeckel; F Oberdorfer; G van Kaick Journal: J Nucl Med Date: 1997-02 Impact factor: 10.057
Authors: J G Tjuvajev; G Stockhammer; R Desai; H Uehara; K Watanabe; B Gansbacher; R G Blasberg Journal: Cancer Res Date: 1995-12-15 Impact factor: 12.701
Authors: J G Tjuvajev; N Avril; T Oku; T Sasajima; T Miyagawa; R Joshi; M Safer; B Beattie; G DiResta; F Daghighian; F Augensen; J Koutcher; J Zweit; J Humm; S M Larson; R Finn; R Blasberg Journal: Cancer Res Date: 1998-10-01 Impact factor: 12.701
Authors: J G Tjuvajev; R Finn; K Watanabe; R Joshi; T Oku; J Kennedy; B Beattie; J Koutcher; S Larson; R G Blasberg Journal: Cancer Res Date: 1996-09-15 Impact factor: 12.701
Authors: Luis A Diaz; Catherine A Foss; Katherine Thornton; Sridhar Nimmagadda; Christopher J Endres; Ovsev Uzuner; Thorsten M Seyler; Slif D Ulrich; Janet Conway; Chetan Bettegowda; Nishant Agrawal; Ian Cheong; Xiaosong Zhang; Paul W Ladenson; Barry N Vogelstein; Michael A Mont; Shibin Zhou; Kenneth W Kinzler; Bert Vogelstein; Martin G Pomper Journal: PLoS One Date: 2007-10-10 Impact factor: 3.240
Authors: David Tung; Gary DeCrescenzo; Dean Welsch; Peter H Cheung; Chetan Bettegowda; Saurabh Saha Journal: World J Microbiol Biotechnol Date: 2014-08-02 Impact factor: 3.312
Authors: Stephanie L Davis; Nicholas A Be; Gyanu Lamichhane; Sridhar Nimmagadda; Martin G Pomper; William R Bishai; Sanjay K Jain Journal: PLoS One Date: 2009-07-16 Impact factor: 3.240